NCT04468997Unknown1 期
Phase I Clinical Trial of Recombinant Anti-VEGF Human Monoclonal Antibody in the Treatment of Wet Age-related Macular Degeneration
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 67
- 试验地点
- 1
- 主要终点
- DLT
研究概览
简要总结
Multicenter study to evaluate the safety and tolerability in patients with wet Age-related macular degeneration (wAMD) treated with intravitreal recombinant humanized anti-VEGF monoclonal antibody
详细描述
According to the results of preclinical pharmacological research and clinical application of bevacizumab in ophthalmology Case, 601 will be developed as a drug candidate for the treatment of ocular diseases such as wAMD .Observe the safety and tolerability of the single and multiple doses of 601 in wAMD patients; study the pharmacokinetic characteristics of single and multiple doses of 601, Observe the Preliminary efficacy of 601 multiple injections with different doses in the treatment of patients with wAMD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 45 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sign informed consent form and willing to be visited at the time specified in the trial;
- •Age ≥45 years and age ≤ 80 years;
- •The study eye must meet the following criteria:
- •Diagnosis of wAMD;
- •The presence of an primary or recurrent active choroidal neovascular (CNV) lesions in subfovea and para-fovea secondary to AMD;
- •Total area of all types of lesions ≤30mm2 (12 optic disc areas)
- •Best EDTRS letter score between 19 and 78(Snellen equivalent of 20/400 to 20/32);
- •No optometric media opacity and pupil shrinkage.
- •Best EDTRS letter score ≥19 (Snellen equivalent of 20/400 or better) in the fellow eyes.
排除标准
- •Any of the following eye conditions:
- •Any eye has active ocular infections (e.g.,blepharitis, keratitis, scleritis, conjunctivitis);
- •History of vitreous hemorrhage in the study eye within 2 months before screening;
- •scarring, fibrosis, or atrophy below with fovea in the study eye;
- •Received any drug treatment for CNV within 120 days prior to screening;
- •History of any following surgery in the study eye (e.g. PDT, macular transposition, Glaucoma filtration, subfoveal photocoagulation, vitrectomy and transpupular hyperthermia, and other surgery at the submacular or others for AMD) within 3 months before screening;
- •CNV in the study eye associated with other ocular diseases such as pathologic myopia, eye trauma, etc
- •History or present of uncontrolled glaucoma, history of glaucoma filtering surgery in the study eye;
- •Subretinal hemorrhage in the study eye, and the bleeding area ≥ 50% area of the total lesion;
- •History of rhegmatogenous retinal detachment or macular hole retinal detachment (stage 3 or 4) , retinal detachment, retinal pigment epithelium tear or macular area traction and macular area preretinal membrane and PCV in the study eye;
- •The study eye has no lens( except intraocular lens) or posterior capsular rupture of the lens;
- •Any of the following general condition are present:
- •Medicines with toxicity to the lens are being used or may be used during the study period;
- •History of allergy to fluorescein sodium and allergies to protein products for treatment or diagnosis, history of allergy to more than two drugs and/or non-drug factors, or suffering from allergic diseases now.
- •History of surgery within 1 months before screening; and/or unhealed wounds, ulcers or fractures currently;
- •Suffering from systemic infections and requiring oral, intramuscular or intravenous medication;
- •History of stroke, myocardial infarction within 6 months before screening;
- •Active diffuse intravascular coagulation and obvious bleeding tendency within 3 months before screening;
- •Systemic immune diseases;
- •Uncontrolled blood pressure control ;
- •Diabetic patients with uncontrolled blood sugar;
- •Any uncontrolled clinical problems (such as severe mental, neurological, cardiovascular, respiratory and other systemic diseases and malignant tumours);
- •Any of the following laboratory tests abnormalities(23-25):
- •Renal function impairment (Cr is 1.5 times higher than the upper limit of normal values in the local laboratory) Liver dysfunction (ALT or AST is 2 times higher than the upper limit of normal value in the local laboratory).
- •Abnormal coagulation function (prothrombin time >= the upper limit of normal value for 3 seconds) and activated partial thromboplastin time >= the upper limit of normal value for 10 seconds);
- •Patients with childbearing age with any of the following conditions:
- •Those who do not use effective contraceptive measures;
- •The following are not excluded:
- •Pregnancy and lactation women (pregnancy is defined as urinary pregnancy test positive in this study);
- •Any other conditions:
- •Participation in any other drug clinical trials (except vitamins and minerals) in the past 1 month before screening ;
- •Researchers think it needs to be ruled out.
研究组 & 干预措施
601 dose level 1 treatment
Experimental
干预措施: Drug 601 (Drug)
601 dose level 2 treatment
Experimental
干预措施: Drug 601 (Drug)
601 dose level 3 treatment
Experimental
干预措施: Drug 601 (Drug)
601 dose level 4 treatment
Experimental
干预措施: Drug 601 (Drug)
601 dose level 5 treatment
Experimental
干预措施: Drug 601 (Drug)
601 dose level 6 treatment
Experimental
干预措施: Drug 601 (Drug)
结局指标
主要结局
DLT
时间窗: From Day 0 up to Day 14
Incidence of dose-limiting toxicities up to the Day 14 visit
MTD
时间窗: From Day 0 up to Day 56/112.
Maximum tolerated dose
次要结局
- t1/2(From Day 0 up to 56/112 days)
- Pharmacokinetic (PK) profile(From Day 0 up to 56/112 days)
- Cmax(From Day 0 up to 56/112 days)
- AUC(From Day 0 up to 56/112 days)
- CRT(From Day 0 up to 56/364 days)
- MRT(From Day 0 up to 56/112 days)
- Biomarker(From Day 0 up to 56/112 days)
- Immunogenicity(From Day 0 up to 56/112 days)
- Vd(From Day 0 up to 56/112 days)
- CL(From Day 0 up to 56/112 days)
- λz(From Day 0 up to 56/112 days)
- diseased region(From Day 0 up to 56/364 days)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study of EXG102-031 in Participants With wAMDNeovascular Age-related Macular DegenerationNCT06183814Hangzhou Jiayin Biotech Ltd42
进行中（未招募）
2 期
The Sahlgrenska Anti-VEGF StudyNeovascular Age-related Macular DegenerationNCT04101877Vastra Gotaland Region402
已完成
1 期
AAVCAGsCD59 for the Treatment of Wet AMDWet Age-related Macular DegenerationNCT03585556Janssen Research & Development, LLC25
已完成
1 期
A Study of Implantation of Retinal Pigment Epithelium in Subjects with Acute Wet Age Related Macular DegenerationAge Related Macular DegenerationNCT01691261Moorfields Eye Hospital NHS Foundation Trust9
撤回
不适用
Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMDPunctate Inner Choroidopathy (PIC)Multifocal ChoroiditisOcular Histoplasmosis SyndromeCentral Serous Chorioretinopathy (CSC)Angioid StreaksTrauma, or Hereditary Eye DiseasesMyopiaChoroidal NeovascularizationNCT01256580Massachusetts Eye and Ear Infirmary